ClinicalTrials.gg
RecruitingNCT06961955FAST NOVEMBERUpdated Dec 9, 2025

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

A Phase 2 interventional study of Radiation Therapy in Breast Cancer, Invasive Carcinoma of Breast and Ductal Breast Carcinoma in Situ, sponsored by University of Utah. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by University of Utah · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.

Planned enrollment
5th of 33
144 · median 34
Started
2025
with 7 others
Phase 2
7 of 33
3 open now
Registered
26th of 33
by date

Among the 33 studies in Breast Neoplasms by University of Utah, this one is the 5th largest by planned enrollment, is one of 8 that started in 2025, is one of 7 in phase 2, and was the 26th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Breast Neoplasms by University of Utah, or all of them as a file.
02

Study summary

The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.

03

Conditions studied

  • Breast Cancer
  • Invasive Carcinoma of Breast
  • Ductal Breast Carcinoma in Situ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participant aged ≥ 18 years.

    --Participants must have at least one of the following risk factors:

    • Grade 3 invasive histology
    • Estrogen receptor positivity less than 5%
    • Lymphovascular invasion
    • Invasive margins \<2mm on surgical pathology
    • DCIS final positive margin
    • Extensive intraductal component
    • Age ≤ 50 years
    • Tumor size > 2 cm
  • confirmed invasive carcinoma or Ductal Carcinoma In Situ (DCIS) of the breast.
  • Breast cancer stage (AJCC v8) T0-3, N0, M0. T0 N0 is allowed if whole breast radiation is recommended by the treating physician.
  • Lumpectomy within 84 days of the start of radiation.
  • Performance Status ≤ 2, or ≥ 50
  • Negative inked histologic margins from lumpectomy, with the exception of a focus of positive margin at the pectoralis fascia.
  • Negative pregnancy test for participants of , evidence of permanent surgical sterilization, or status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • \< 50 years of age:

      • Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
      • Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
    • ≥ 50 years of age:

      • Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
      • Had radiation-induced menopause with last menses >1 year ago; or
      • Had chemotherapy-induced menopause with last menses >1 year ago
  • Sexually active participants of childbearing potential must agree to use highly effective method of (defined in Section 5.4.1) during the course of radiation and for 30 days after radiation.
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Bilateral breast cancer.
  • Prior radiation therapy to the chest.
  • Prior chemotherapy.
  • Recurrent disease.
  • Known or node positive.
  • Major chest surgery which is expected to impact study participation 8 weeks prior to starting study drug.
  • Prior breast in either breast.
  • The diagnosis of any other malignancy which, in the opinion of the Investigator, is likely to negatively impact the subject's safety or ability to participate in the study.
  • Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders:

      • Congestive heart failure Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.
      • Stroke (including [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.
    • Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow, social/ psychological issues, etc.)
  • Significant post lumpectomy complications requiring an unplanned re-operation for surgical complications or admission for IV antibiotics. Re-operation for margins evaluation or nodal evaluation is acceptable. Draining of a seroma is not considered a complication unless it has become infected.
  • Breast neuroendocrine carcinoma or sarcoma histology.
  • Radiation sensitizing disease or condition (e.g. connective tissue disease, li fremani, etc.).
  • Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give , comply with the study protocol or complete the study.
  • Participants receiving concurrent radiation sensitizing medications or therapies.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    5 fractions of radiotherapy (Arm 1)

    Radiation: Radiation Therapy

  • Active comparator
    9 fractions of radio therapy (Arm 2)

    Radiation: Radiation Therapy

Interventions

  • RadiationRadiation Therapy

    Undergo hypofractionated radiation therapy

06

What researchers measure

Primary outcomes

  1. 24-month Mean breast overall satisfaction Breast - Q scores with 5 fractions of radiation is non-inferior in patient reported outcomes.

    To evaluate non-inferiority of 24-month Breast-Q satisfaction with breast score with 5 versus 9 fractions of radiation.

    Time frame: 3 years

Secondary outcomes

  1. Evaluate acute and late radiation-related adverse events (AEs) and serious adverse events (SAEs) between the two arms, characterized by type

    To estimate the incidence of acute and late radiation complications between the two arms, based on CTCAE 5.0 toxicity.

    Time frame: 5 years

  2. Evaluate acute and late radiation-related adverse events (AEs) and serious adverse events (SAEs) between the two arms, characterized by severity (as defined by the NIH CTCAE, version 5.0)

    To estimate the incidence of acute and late radiation complications between the two arms, based on CTCAE 5.0 toxicity.

    Time frame: 5 years

  3. Evaluate acute and late radiation-related adverse events (AEs) and serious adverse events (SAEs) between the two arms, characterized by seriousness

    To estimate the incidence of acute and late radiation complications between the two arms, based on CTCAE 5.0 toxicity.

    Time frame: 5 years

  4. Evaluate acute and late radiation-related adverse events (AEs) and serious adverse events (SAEs) between the two arms, characterized by duration

    To estimate the incidence of acute and late radiation complications between the two arms, based on CTCAE 5.0 toxicity.

    Time frame: 5 years

  5. Evaluate acute and late radiation-related adverse events (AEs) and serious adverse events (SAEs) between the two arms, characterized by relationship to study treatment.

    To estimate the incidence of acute and late radiation complications between the two arms, based on CTCAE 5.0 toxicity.

    Time frame: 5 years

  6. Evaluate non-inferiority of local and local regional recurrence rate in the treatment arms.

    To evaluate non-inferiority of the local and local regional recurrence rate between the two arms.

    Time frame: 8 years

  7. Evaluate non-inferiority of a change in cosmetic scores in the treatment arms with pre-radiation scores to post 24-month scores using the UK photographic assessment and EORTC scales.

    To evaluate non-inferiority of the breast photographic cosmetic outcomes of the UK and EORTC scales

    Time frame: 5 years

  8. 60-month mean breast overall satisfaction Breast-Q scores with 5 fractions of radiation is non-inferior in patient reported outcomes.

    To evaluate non-inferiority of the mean Breast-Q scores with 5 fractions of radiation at 60 months.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2030, 60 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 8, 2025
StartActual
May 21, 2025
Primary completionEst.
May 2030
CompletionEst.
May 2033
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961955
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
May 8, 2025
Start date
May 21, 2025
Primary completion
May 2030 (estimated)
Completion
May 2033 (estimated)
Last update
Dec 9, 2025

Study contacts

Rachel Kingsford
Contact
rachel.kingsford@hci.utah.edu
801-585-0115
David Samuel
Contact
david.samuel@hci.utah.edu
801-587-4713
Matthew R. Poppe, MD
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion